New Zealand markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.65-1.23 (-3.16%)
At close: 04:00PM EST
37.61 -0.04 (-0.11%)
After hours: 07:19PM EST
Full screen
Trade prices are not sourced from all markets
Previous close38.88
Bid0.00 x 900
Ask0.00 x 800
Day's range37.41 - 39.50
52-week range34.86 - 53.23
Avg. volume2,559,439
Market cap16.171B
Beta (5Y monthly)N/A
PE ratio (TTM)19.55
EPS (TTM)1.93
Earnings date15 Feb 2022 - 21 Feb 2022
Forward dividend & yield0.68 (1.75%)
Ex-dividend date18 Nov 2021
1y target est51.43
  • GlobeNewswire

    Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

    NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is

  • GlobeNewswire

    Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

    Provides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closi

  • GlobeNewswire

    Royalty Pharma Reports Third Quarter 2021 Results

    Net cash provided from operating activities (GAAP) of $470 million; Adjusted Cash Receipts(1) (non-GAAP) of $587 million and Adjusted Cash Flow(2) (non-GAAP) of $441 millionAnnounced transactions of up to $2.8 billion in 2021, including $2.1 billion in upfront paymentsRaises 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,110 to $2,130 million NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 an